Doses of methotrexate and leflunomide PMR and in RA
Are doses of methotrexate and leflunomide the same in polymyalgia rheumatica (PMR) and in rheumatoid arthritis (RA)?
Are doses of methotrexate and leflunomide the same in polymyalgia rheumatica (PMR) and in rheumatoid arthritis (RA)?
Does treatment really reduce fracture risk in patients with osteoporosis?
Preradiographic axial spondyloarthritis seems to be a rather nonspecific diagnosis because a significant proportion of patients do not progress to ankylosing spondylitis. How can we improve our diagnostic accuracy?
When should we consider treatment of osteoporosis? What is the best method to guide decision-making (Fracture Risk Assessment Tool, densitometry)?
Malignancies often mimic polymyalgia rheumatica (PMR), especially in the first months of the disease. Are there any distinguishing features of paraneoplastic PMR-like syndromes?
Do we use intravenous glucocorticosteroids in patients with polymyalgia rheumatica? What are the doses of intramuscular glucocorticosteroids in these patients?
Is there a risk that repetitive sports-related injuries accelerate the progression of spondyloarthritis?
Should we perform ultrasound in patients with polymyalgia rheumatica?
Does anti-tumor necrosis factor therapy inhibit the progression of radiological changes in the spine?